ImaginAb Appoints Jeff Bailey to Board of Directors

Pharmaceutical industry veteran and business operations specialist has history of supporting innovation, commercialization of medical imaging technology
INGLEWOOD, Calif., September 23, 2015—ImaginAb Inc., a clinical-stage immune imaging company, today announced the appointment of Jeff Bailey to its board of directors. Mr. Bailey brings nearly three decades of leadership in pharmaceuticals and diagnostic imaging. He most recently served as president and chief executive officer of Lantheus Medical Imaging Inc.

"Jeff's wealth of experience in developing and commercializing innovative imaging products is a tremendous asset to ImaginAb, as is his successful history in the global pharmaceutical sector," said Abbie Celniker, Ph.D., chairwoman of ImaginAb. "The board looks forward to utilizing Jeff's exceptional knowledge as ImaginAb makes rapid progress in advancing its novel antibody-driven approach to imaging human immune response."

At Lantheus, Mr. Bailey oversaw business operations, including strategic partnerships and commercial efforts for more than a dozen marketed imaging products. He also was closely involved in clinical and regulatory efforts for several molecular imaging agents at various stages of development, and has been commended for his ability to grow revenues and margins since assuming the CEO post in January 2013. He retired from Lantheus in August and remains with the company as a consultant.

"ImaginAb's products for visualizing the immune system have the potential to play a critical role in patient selection and monitoring for cancer immunotherapies, answering a very real need in the marketplace," Mr. Bailey said. "Patients, physicians, payers and pharmaceutical companies are all seeking greater clarity in the immuno-oncology space, and ImaginAb is working on a first-in-class solution to provide just that."

Prior to taking the helm at Lantheus, Mr. Bailey served as chief operating officer of Fougera Pharmaceuticals and chief commercial officer for King Pharmaceuticals. Previously, he led the northwest operating unit team of Novartis Pharmaceuticals as president and general manager. Earlier, he served in key supply chain and commercial leadership roles for Johnson & Johnson including national sales director for Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Mr. Bailey earned a business degree from Rutgers University-New Brunswick.

At ImaginAb, Mr. Bailey will work alongside other experienced board members including Dr. Celniker, CEO of Eleven Biotherapeutics; Campbell Murray, M.D., managing director of the Novartis Venture Fund; K. Leonard Judson, president and managing director of Cycad Group, Anna M. Wu, Ph.D., co-founder of ImaginAb and professor in Pathology and Laboratory Medicine at the David Geffen School of Medicine at University of California, Los Angeles; and Isaac Bright, M.D., partner on the Merieux Development management team.

About ImaginAb
ImaginAb Inc. is an immune imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling truly personalized medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes. ImaginAb's products have the potential to improve patient care and lower healthcare costs. For more information about ImaginAb's pipeline and technology, visit

Media Contact:
Jason Spark
Canale Communications for ImaginAb Inc.
[email protected]